https://www.amyndas.com/conjugation-to-albumin-binding-molecule-tags-as-a-strategy-to-improve-both-efficacy-and-pharmacokinetic-properties-of-the-complement-inhibitor-compstatin-2/ 2015-02-25T19:17:20+00:00 https://www.amyndas.com/595/ 2015-03-10T16:37:22+00:00 https://www.amyndas.com/genetic-and-intervention-studies-implicating-complement-c3-as-a-major-target-for-the-treatment-of-periodontitis-2/ 2015-03-12T14:36:29+00:00 https://www.amyndas.com/peptide-inhibitors-of-c3-activation-as-a-novel-strategy-of-complement-inhibition-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria/ 2015-03-12T14:37:09+00:00 https://www.amyndas.com/new-analogs-of-the-clinical-complement-inhibitor-compstatin-with-with-subnanomolar-affinity-and-enhanced-pharmacokinetic-properties/ 2015-03-12T14:37:37+00:00 https://www.amyndas.com/novel-analogues-of-the-therapeutic-complement-inhibitor-compstatin-with-significantly-improved-affinity-and-potency/ 2015-03-12T14:39:03+00:00 https://www.amyndas.com/amyndas-wins-pharmaceutical-innovation-competition/ 2015-03-17T13:11:45+00:00 https://www.amyndas.com/wp-content/uploads/2014/11/sfee-e1426084658146.png https://www.amyndas.com/amyndas-features-in-%ce%b2%ce%b7%ce%bc%ce%b1-on-of-the-widest-read-greek-national-sunday-newspapers/ 2015-03-17T13:12:33+00:00 https://www.amyndas.com/769/ 2015-03-19T15:04:54+00:00 https://www.amyndas.com/amyndas-features-in-two-of-the-widest-read-greek-national-sunday-newspapers/ 2015-03-24T13:26:15+00:00 https://www.amyndas.com/wp-content/uploads/2014/11/3kathimerini.jpg https://www.amyndas.com/bioworld-two-pronged-amyndas-targets-complement-based-anti-inflammatories/ 2015-03-24T13:32:19+00:00 https://www.amyndas.com/biocentury-amyndas-developing-super-compstatins-for-complement-mediated-disorders/ 2015-03-25T22:05:48+00:00 https://www.amyndas.com/amyndas-participates-in-a-major-publication-on-paroxysmal-nocturnal-hemoglobinuria-pnh/ 2015-03-31T14:05:04+00:00 https://www.amyndas.com/wp-content/uploads/2015/02/Twitter-picture.jpg https://www.amyndas.com/compstatin-a-c3-targeted-complement-inhibitor-reaching-its-prime-for-bedside-intervention-4/ 2015-05-13T14:40:28+00:00 https://www.amyndas.com/1061/ 2015-08-24T17:23:31+00:00 https://www.amyndas.com/complement-inhibition-prevents-oncolytic-vaccinia-virus-neutralization-in-immune-humans-and-cynomolgus-macaques/ 2015-08-24T20:40:03+00:00 https://www.amyndas.com/complement-inhibition-prevents-oncolytic-vaccinia-virus-neutralization-in-immune-humans-and-cynomolgus-macaques-pubmed-ncbi/ 2015-08-24T21:20:56+00:00 https://www.amyndas.com/compstatin-analog-cp40-inhibits-complement-dysregulation-in-vitro-in-c3-glomerulopathy/ 2015-08-25T13:47:08+00:00 https://www.amyndas.com/complement-inhibition-prevents-oncolytic-vaccinia-virus-neutralization-in-immune-humans-and-cynomolgus-macaques-2/ 2015-08-25T18:47:35+00:00 https://www.amyndas.com/compstatin-analog-cp40-inhibits-complement-dysregulation-in-vitro-in-c3-glomerulopathy-2/ 2015-08-29T01:48:03+00:00 https://www.amyndas.com/therapeutic-c3-inhibitor-cp40-abrogates-complement-activation-induced-by-modern-hemodialysis-filters/ 2015-08-29T01:54:55+00:00 https://www.amyndas.com/fda-grants-orphan-drug-designation-for-pnh-to-amyndas-pharmaceuticals-novel-complement-inhibitor/ 2015-08-29T02:15:15+00:00 https://www.amyndas.com/ema-grants-orphan-drug-designation-for-pnh-to-amyndas-pharmaceuticals-novel-complement-inhibitor/ 2015-08-29T02:18:23+00:00 https://www.amyndas.com/press-release-the-aplastic-anemia-mds-international-foundation-supports-amyndas-pharmaceuticals-novel-complement-inhibitor-amy-101/ 2015-09-23T03:13:07+00:00 https://www.amyndas.com/using-an-in-vitro-xenoantibody-mediated-complement-dependent-cytotoxicity-model-to-evaluate-the-complement-inhibitory-activity-of-the-peptidic-c3-inhibitor-cp40/ 2015-11-22T00:37:36+00:00 https://www.amyndas.com/press-release-amyndas-lead-candidate-amy-101-receives-orphan-drug-status-from-the-fda-and-the-ema-for-the-treatment-of-c3-glomerulopathy/ 2016-03-04T03:06:18+00:00 https://www.amyndas.com/study-on-reversing-periodontitis-with-cp40-features-on-6-abc-news/ 2016-05-13T22:40:24+00:00 https://www.amyndas.com/study-on-inhibiting-pre-exisitng-natural-periodontitis-with-cp40-receives-high-altmetric-score/ 2016-05-14T04:15:22+00:00 https://www.amyndas.com/complement-therapeutics-in-inflammatory-diseases-promising-drug-candidates-for-c3-targeted-intervention/ 2017-10-15T19:48:56+00:00 https://www.amyndas.com/complement-in-cancer-untangling-an-intricate-relationship/ 2017-10-15T19:52:52+00:00 https://www.amyndas.com/high-fat-diet-induced-complement-activation-mediates-intestinal-inflammation-and-neoplasia-independent-of-obesity/ 2017-10-16T10:33:23+00:00 https://www.amyndas.com/new-safety-and-efficacy-of-the-complement-inhibitor-amy-101-in-a-natural-model-of-periodontitis-in-non-human-primates/ 2017-10-16T10:37:04+00:00 https://www.amyndas.com/iron-oxide-nanoparticles-induce-cytokine-secretion-in-a-complement-dependent-manner-in-a-human-whole-blood-model/ 2017-10-16T10:51:12+00:00 https://www.amyndas.com/inhibition-of-pre-existing-natural-periodontitis-in-non-human-primates-by-a-locally-administered-peptide-inhibitor-of-complement-c3/ 2017-10-16T10:55:40+00:00 https://www.amyndas.com/synthesis-and-activity-of-thioether-containing-analogues-of-the-complement-inhibitor-compstatin/ 2017-10-16T11:00:31+00:00 https://www.amyndas.com/alginate-microbeads-are-coagulation-compatible-while-alginate-microcapsules-activate-coagulation-secondary-to-complement-or-directly-through-fxii/ 2017-10-16T11:01:56+00:00 https://www.amyndas.com/therapeutic-c3-inhibitor-cp40-abrogates-complement-activation-induced-by-modern-hemodialysis-filters-2/ 2017-10-16T11:03:34+00:00 https://www.amyndas.com/local-endothelial-complement-activation-reverses-endothelial-quiescence-enabling-t-cell-homing-and-tumor-control-during-t-cell-immunotherapy/ 2017-11-01T01:24:15+00:00 https://www.amyndas.com/complement-inhibition-enables-tumor-delivery-of-lcmv-glycoprotein-pseudotyped-viruses-in-the-presence-of-antiviral-antibodies/ 2017-11-01T01:26:08+00:00 https://www.amyndas.com/complement-c3-targeted-therapy-replacing-long-held-assertions-with-evidence-based-discovery/ 2017-11-02T21:14:50+00:00 https://www.amyndas.com/from-orphan-drugs-to-adopted-therapies-advancing-c3-targeted-intervention-to-the-clinical-stage/ 2017-11-02T21:16:21+00:00 https://www.amyndas.com/complement-inhibition-in-pre-clinical-models-of-periodontitis-and-prospects-for-clinical-application/ 2017-11-06T01:50:11+00:00 https://www.amyndas.com/applying-complement-therapeutics-to-rare-diseases/ 2017-11-06T01:51:49+00:00 https://www.amyndas.com/press-release-penn-team-reverses-signs-of-naturally-occurring-chronic-periodontitis/ 2017-11-17T02:32:23+00:00 https://www.amyndas.com/medicalresearch-com-cp40-reverses-periodontitis/ 2017-11-17T02:33:09+00:00 https://www.amyndas.com/press-release-whats-eating-the-erythrocytes/ 2017-11-17T02:34:06+00:00 https://www.amyndas.com/penn-immunologist-to-develop-drugs-for-renal-disease/ 2017-11-17T02:35:59+00:00 https://www.amyndas.com/penn-study-shows-way-to-make-treatment-of-rare-blood-disorder-more-affordable-and-effective-2/ 2017-11-17T02:37:19+00:00 https://www.amyndas.com/press-release-penn-team-identifies-promising-new-target-for-gum-disease-treatment/ 2017-11-17T02:38:11+00:00 https://www.amyndas.com/press-release-amyndas-pharmaceuticals-announces-positive-results-from-a-phase-i-trial-of-its-complement-c3-inhibitor-amy-101/ 2017-12-13T18:33:47+00:00 https://www.amyndas.com/high-point-clinical-trials-center-and-amyndas-pharmaceuticals-announce-the-completion-of-the-complement-c3-inhibitor-amy-101-first-in-human-study/ 2018-03-30T02:43:58+00:00 https://www.amyndas.com/high-point-clinical-trials-center-and-amyndas-pharmaceuticals-announce-the-completion-of-the-complement-c3-inhibitor-amy-101-first-in-human-study-2/ 2019-12-10T18:34:43+00:00 https://www.amyndas.com/amyndas-pharmaceuticals-announces-positive-results-from-a-phase-i-trial-of-its-new-complement-c3-inhibitor-amy-101/ 2019-12-10T18:34:53+00:00 https://www.amyndas.com/method-development-and-validation-for-the-quantitation-of-the-complement-inhibitor-cp40-in-human-and-cynomolgus-monkey-plasma-by-uplc-esi-ms/ 2020-04-02T21:25:12+00:00 https://www.amyndas.com/the-renaissance-of-complement-therapeutics/ 2020-04-03T00:57:33+00:00 http://amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg http://amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/prolonged-intraocular-residence-and-retinal-tissue-distribution-of-a-fourth-generation-compstatin-based-c3-inhibitor-in-non-human-primates/ 2020-04-03T01:03:18+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/complement-as-a-target-in-covid-19/ 2020-06-02T03:52:26+00:00 http://amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg http://amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/the-first-case-of-covid-19-treated-with-the-complement-c3-inhibitor-amy-101/ 2020-06-02T15:23:15+00:00 https://www.amyndas.com/wp-content/uploads/2015/03/Final-Shutterstock-microscope-e1426777022680.jpg http://amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg http://amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/covid-19/ 2020-06-04T18:49:33+00:00 https://www.amyndas.com/wp-content/uploads/2015/03/Final-shutterstock-hands-circle.jpg https://www.amyndas.com/amyndas-pharmaceuticals-initiates-phase-2a-study-of-amy-101-in-adults-with-periodontal-inflammation-and-gingivitis-2/ 2020-06-05T18:31:35+00:00 https://www.amyndas.com/amyndas-pharmaceuticals-initiates-phase-2a-study-of-amy-101-in-adults-with-periodontal-inflammation-and-gingivitis/ 2020-06-07T02:17:17+00:00 https://www.amyndas.com/amyndas-pharmaceuticals-initiates-phase-2a-study-of-amy-101-in-adults-with-periodontal-inflammation-and-gingivitis-greek-translation/ 2020-06-07T02:22:23+00:00 https://www.amyndas.com/periodontitis-trial-short-description-gr/ 2020-06-08T05:03:28+00:00 https://www.amyndas.com/%cf%84%ce%bf-%ce%b2%ce%ae%ce%bc%ce%b1-%ce%bd%ce%ad%ce%b1-%cf%86%ce%b1%cf%81%ce%bc%ce%b1%ce%ba%ce%b5%cf%85%cf%84%ce%b9%ce%ba%ce%ae-%ce%b5%ce%bb%cf%80%ce%af%ce%b4%ce%b1-%ce%b5%ce%bd%ce%ac%ce%bd%cf%84/ 2020-06-15T21:30:26+00:00 https://www.amyndas.com/%cf%84%ce%bf-%ce%b2%ce%ae%ce%bc%ce%b1-%ce%b5%ce%bb%ce%bb%ce%b7%ce%bd%ce%b9%ce%ba%cf%8c-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%b5%ce%bd%ce%ac%ce%bd%cf%84%ce%b9%ce%b1-%cf%83%cf%84%ce%b7%ce%bd-c/ 2020-06-15T21:31:39+00:00 https://www.amyndas.com/quartesian-announces-amyndas-partnership-for-covid-19-clinical-trial/ 2020-06-17T00:43:27+00:00 https://www.amyndas.com/complement-c3-vs-c5-inhibition-in-severe-covid-19-early-clinical-findings-reveal-differential-biological-efficacy/ 2020-09-20T20:34:40+00:00 http://amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/%cf%84%ce%bf-%ce%b2%ce%ae%ce%bc%ce%b1-%ce%ba%ce%bf%cf%81%cf%89%ce%bd%ce%bf%cf%8a%cf%8c%cf%82-%ce%b5%ce%bb%ce%bb%ce%b7%ce%bd%ce%b9%ce%ba%cf%8c-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%b3%ce%b9/ 2020-09-22T01:18:29+00:00 https://www.amyndas.com/complement-and-tissue-factor-enriched-neutrophil-extracellular-traps-are-key-drivers-in-covid-19-immunothrombosis/ 2020-10-27T13:27:55+00:00 http://amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg http://amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/%cf%84%ce%bf-%ce%b2%ce%ae%ce%bc%ce%b1-covid-19-%ce%b5%ce%bb%ce%bb%ce%b7%ce%bd%ce%b9%ce%ba%cf%8c-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%b8%ce%b1-%ce%b4%ce%bf%ce%ba%ce%b9%ce%bc%ce%b1%cf%83/ 2020-11-09T20:10:05+00:00 https://www.amyndas.com/%ce%b5%ce%bb%ce%bb%ce%b7%ce%bd%ce%b9%ce%ba%cf%8c-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%b1%ce%bd%ce%bf%ce%af%ce%b3%ce%b5%ce%b9-%ce%bd%ce%ad%ce%bf%cf%85%cf%82-%ce%b4%cf%81%cf%8c%ce%bc%ce%bf/ 2021-03-11T16:15:46+00:00 https://www.amyndas.com/%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%cf%80%ce%b5%cf%81%ce%b9%ce%bf%ce%b4%ce%bf%ce%bd%cf%84%ce%af%cf%84%ce%b9%ce%b4%ce%b1/ 2021-03-11T16:36:29+00:00 https://www.amyndas.com/amyndas-periodontitis-amy101/ 2021-03-21T01:03:13+00:00 https://www.amyndas.com/businesswire-amyndas-periodontal/ 2021-05-24T17:52:47+00:00 https://www.amyndas.com/phase2a-amy101-periodontal/ 2021-10-08T18:09:57+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/endorsement-c3-perio/ 2021-10-08T18:10:56+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/host-modulation-perio/ 2021-10-08T18:11:39+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/forsyth-dentech-2021-presentation-by-dr-yancopoulou-amyndas-managing-director/ 2021-10-11T00:18:13+00:00 https://www.amyndas.com/jci-video-complement-c3-inhibitor-amy-101-in-adults-with-periodontal-inflammation-clinical-trial/ 2021-12-04T00:35:38+00:00 https://www.amyndas.com/review-compstatins-the-dawn-of-clinical-c3-targeted-complement-inhibition/ 2022-01-26T21:00:16+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif https://www.amyndas.com/eustm-novel-transformative-treatment-for-periodontal-disease/ 2022-10-06T15:16:31+00:00 https://www.amyndas.com/iatronet-gr-%cf%86%ce%ac%cf%81%ce%bc%ce%b1%ce%ba%ce%bf-%ce%bc%ce%b5-%ce%b5%ce%bb%ce%bb%ce%b7%ce%bd%ce%b9%ce%ba%ce%ae-%cf%85%cf%80%ce%bf%ce%b3%cf%81%ce%b1%cf%86%ce%ae-%ce%b3%ce%b9%ce%b1-%cf%84/ 2023-02-23T22:05:59+00:00 https://www.amyndas.com/complement-c3-inhibition-in-severe-covid-19-using-compstatin-amy-101/ 2023-03-15T00:25:37+00:00 https://www.amyndas.com/wp-content/uploads/2017/12/pubmedlogo.jpg https://www.amyndas.com/wp-content/uploads/2017/12/pdficon.gif